gepirone

It finally got approved (Sept 2023) after years of rejections from the FDA. "Studied in over 5,000 patients, Travivo (Gepirone) has been found to have a favorable safety profile and be well-tolerated. The drug's unique single mechanism of targeted 5HT1a agonism, allows for the relief of...